Where Moderna Stands With Analysts
Portfolio Pulse from Benzinga Insights
Moderna (NASDAQ:MRNA) has received mixed analyst ratings in the last quarter, with one bullish, two indifferent, and one somewhat bearish. The average price target is $152.25, which is higher than the current price of $125.8. However, this represents an 18.29% decrease from the previous average price target of $186.33.
July 24, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mixed analyst ratings and a lower average price target could lead to uncertainty among investors, potentially impacting Moderna's stock price.
Analyst ratings can influence investor sentiment. The mixed ratings and lower price target for Moderna may create uncertainty, which could lead to volatility in the stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100